FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]

Pour des fins de recherche uniquement. Déclaration complète →

Recherche/Papier
Retour à la bibliothèque de recherche
PubMedMeta-AnalysisSujets humains

Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.

Sinha Binayak, Ghosal Samit
Obesity (Silver Spring, Md.)2025DOI: 10.1002/oby.24360
GLP-1 receptor agonistsdual agonistsretatrutide

Note de qualité

8/10

Citations

0

Sujets

Humain

Analyse Peptide Contacts

Study Design

By pooling data across multiple studies, this meta-analysis achieves statistical power that no individual trial could match alone. The combined sample size strengthens confidence in the effect estimates reported.

Our Assessment

Quality Assessment: 8/10 — This paper meets our highest quality thresholds. The methodology is well-designed, the statistical analysis is appropriate, and the conclusions are well-supported by the data presented. This is a reference-grade study for the peptides it covers.

Findings in Context

These findings advance our understanding of GLP-1 receptor agonists, dual agonists, retatrutide in meaningful ways. The human-subjects design makes these results particularly relevant for clinical translation.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: This is high-quality human evidence for GLP-1 receptor agonists, dual agonists, retatrutide. If you're tracking the research landscape for these compounds, this paper deserves a close read.

Trouvailles clés

The study found that retatrutide and dual agonists provided the highest mean weight loss (-11.0 kg) compared to GLP-1 receptor agonists (-9.0 kg), with retatrutide excelling in achieving ≥ 15% weight loss, though it also had the highest adverse event risk.

Limites

The study's limitations include potential publication bias and heterogeneity among included trials, as well as the impact of type 2 diabetes on treatment efficacy.

Comment interpréter cette recherche

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Analyse Peptide Contacts

Highlighting the comparative effectiveness and safety of GLP-1 receptor agonists, dual agonists, and retatrutide for weight loss in patients with overweight or obesity.

GLP-1 receptor agonistsdual agonistsretatrutide

New Insights into Weight Loss Therapies: GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide

Published: May 16, 2026 | Source: Obesity (Silver Spring, Md.) (2025) | Category: GLP-1 receptor agonists, dual agonists, retatrutide

Overview

A recent study published in Obesity offers a comprehensive comparison of the efficacy and safety profiles of GLP-1 receptor agonists (GLP-1RAs), dual agonists, and retatrutide for weight loss among adults with overweight or obesity. The findings suggest that while these therapies are effective, they come with varying levels of risk and benefits depending on patient characteristics.

Study Background

Previous research has highlighted the potential of GLP-1 receptor agonists in aiding weight management, but there was a need to understand how newer agents like dual agonists and retatrutide compare. This study aimed to fill that gap by conducting a Bayesian network meta-analysis (NMA) to evaluate these treatments comprehensively.

What the Research Found

The analysis included 19 randomized controlled trials involving over 29,500 participants with BMI ≥ 25 kg/m². The results showed that retatrutide and dual agonists achieved a mean weight loss of -11.0 kg, surpassing GLP-1RAs at -9.0 kg. Retatrutide was particularly effective in achieving ≥ 15% weight loss, with an odds ratio (OR) of 54.6 compared to GLP-1RAs and dual agonists at ORs of 16.4 and 9.0 respectively.

However, retatrutide also had the highest adverse event risk among the three types of treatments. The study further noted that type 2 diabetes mellitus (T2DM) reduced weight loss efficacy for both GLP-1RAs and dual agonists by approximately 5 kg on average. Additionally, female-dominant or high-BMI cohorts showed enhanced outcomes with these therapies.

What This Means for Peptide Users

For patients considering peptide therapy for weight management, the study provides valuable insights into the comparative benefits and risks of different treatment options. Retatrutide offers superior efficacy but comes with a higher risk of adverse events, making it less suitable for all patient profiles. Dual agonists appear to offer a balanced approach between effectiveness and safety.

Limitations and Caveats

The study acknowledges several limitations, including potential publication bias and heterogeneity among the included trials. The impact of T2DM on treatment efficacy also complicates the interpretation of results, suggesting that personalized treatment selection based on patient characteristics is crucial.

How This Compares to Previous Research

While previous studies have highlighted the effectiveness of GLP-1RAs for weight loss, this study provides a more nuanced comparison by including dual agonists and retatrutide. The findings align with earlier research in terms of efficacy but offer new insights into safety profiles and patient-specific outcomes.

Our Analysis

PeptideVault's critical assessment suggests that while the study offers valuable comparative data on GLP-1RAs, dual agonists, and retatrutide, its limitations must be considered. The high adverse event risk associated with retatrutide underscores the importance of personalized treatment approaches in clinical practice.

Key Takeaways

  • Retatrutide is highly effective for weight loss but carries a higher risk of adverse events.
  • Dual agonists provide an optimal balance between efficacy and safety, making them suitable for broader patient profiles.
  • Personalized treatment selection based on individual characteristics such as T2DM status and BMI is recommended.

Original Source

Citation: Sinha Binayak, Ghosal Samit (2025). Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.. Obesity (Silver Spring, Md.). DOI: 10.1002/oby.24360

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Note de l'éditeur

Cette analyse a été rédigée par l'équipe de recherche de Peptide Contacts pour rendre les découvertes complexes accessibles à la communauté des peptides. Nous encourageons les lecteurs à vérifier le papier source pour une méthodologie et des données complètes. Pour plus d'informations sur GLP-1 receptor agonists, explorez nos guides de recherche.

Citation

Sinha Binayak, Ghosal Samit. (2025). Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.. Obesity (Silver Spring, Md.). https://doi.org/10.1002/oby.24360

Voir le texte intégral sur PubMed

Papiers connexes

Explorer davantage

Ce contenu est dérivé d'une recherche peer-reviewed pour des fins éducatives uniquement. Il ne constitue pas un avis médical. Consultez toujours un fournisseur de soins de santé qualifié avant d'utiliser tout traitement basé sur les peptides.